For nearly four decades, mention of the Ebola virus has evoked death and terror, yet a simple factor — money — has stood in the way of erasing the curse, experts say.
Despite its evil reputation, Ebola breaks out only rarely in brief if murderous spurts in impoverished African countries.
That tiny — and poor — market means that the disease has been a very low priority for Big Pharma, given the hundreds of millions of dollars it can take to devise a new drug or vaccine.
Photo: AFP
Today, after years of low-key progress with the Pentagon as its main funder, the search for vaccines and drugs for Ebola has been thrown into higher gear and — for now — the profit factor has been put to one side.
“Until this west African epidemic, Ebola was not a public health problem and [was] a really rare disease,” says Peter Piot, director of the London School of Hygiene and Tropical Medicine, who codiscovered the Ebola virus in 1976.
“There was very little interest in all quarters, not just pharma,” Piot said in an e-mail. “Things have changed now, and two major companies are investing in a vaccine — GSK [GlaxoSmithKline] and [Johnson & Johnson subsidiary] Janssen.”
Sylvain Baize, in charge of the Viral Hemorrhagic Fevers Reference Center at France’s Pasteur Institute, said Ebola had claimed fewer than 2,000 lives in almost 40 years, a minute toll compared with other diseases.
“If these 2,000 deaths had occurred in industrialized countries, things may have been different, but it was 2,000 dead in the middle of Africa, so nobody cared very much,” Baize said sardonically.
Ebola’s extraordinary lethality was another reason that it never became a top target for research, he said.
“It has to be confined in a top-security ‘P4’ laboratory, of which there are very few in the world, so there are not many people who in fact can work on it,” Baize said.
The recent shakeup has been spurred by an epidemic in four west African countries — Guinea, Liberia, Nigeria and Sierra Leone — that has killed more than 2,400 people, about half of the confirmed infections. The outbreak has caused social dislocation and economic disruption, while breeding fears in neighboring countries and in Europe of the disease’s potential to spread.
The two treatments and two vaccines most advanced in the research pipeline are still at the very earliest testing stages to see whether they are safe — and if they work.
On Aug. 12, the WHO gave the green light to using experimental drugs for Ebola treatment, saying it would be ethical given the extent of the current crisis and because no cure or vaccine so far exists. Human trials typically take several years under an exhaustive, three-phase vetting procedure.
On Sept. 5, the WHO voiced hopes that a vaccine would be available in November for frontline health workers.
If this fast-tracking process yields results, it raises the next question: Who will pay to manufacture the drug and distribute it?
“Ebola is a classic orphan disease,” said Annette Rid, a doctor of bioethics at King’s College London, adding that public funds, charities and institutional donors would have to stump up the seed money.
“Once it is established that a therapy or vaccine is effective, stockpiles need to be established in those African countries where Ebola is likely to re-emerge,” Piot said. “This can be funded by the international community and done under the aegis of the WHO.”
US National Institute of Allergy and Infectious Diseases director Anthony Fauci said he was increasingly optimistic that Big Pharma would play a role, given the scale of the crisis.
“I think there was previously no incentive, but now that everyone sees that it is a big problem, we are getting more and more companies involved,” he said.
Seth Berkley, head of the GAVI Alliance, a public-private partnership designed to bring vaccines to poor countries, said a panoply of tools existed for harnessing the profit motive.
“You can directly finance the vaccine technology transfer, you can incentivize companies by funding them directly, you can create an advanced market commitment with supplemental funds to try to make it a good deal for business, you can create a long-term plan for buying the vaccines as an incentive,” he said. “There is a range of mechanisms there and it could be done rather quickly.”
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure